Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug ...

Today, as the program celebrates 40 years of education and training focused on the integration of research with patient care, ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical ...

The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory ...

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 ...

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress ...

Duality Bio (HKEX: 9606.HK) presented the preliminary data of two clinical trials, HER3 ADC candidate DB-1310 and B7H3 ADC candidate DB-1311/BNT324, which is being jointly developed with BioNTech ...